Gyre Therapeutics
GYRE
55 hedge funds and large institutions have $54.1M invested in Gyre Therapeutics in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 14 closing their positions.
104% more call options, than puts
Call options by funds: $334K | Put options by funds: $164K
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 63 → 55 (-8)
50% less capital invested
Capital invested by funds: $107M → $54.1M (-$53.1M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$420K |
| 2 |
D.E. Shaw & Co
New York
|
+$408K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$405K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$341K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$6.59M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.19M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$727K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$541K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$358K |
GYRE Hedge Fund Activity: Q3 2014 in Review
55 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2014, worth a combined $54.1M — down 50% from $107M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GYRE and 6 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 18 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $420K. The largest seller was Franklin Resources, cutting an estimated $6.59M.
- 55 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2014, down from 63 in Q2 2014.
- Funds reported $54.1M of Gyre Therapeutics stock for Q3 2014, down 50% quarter-over-quarter.
- 6 funds opened new Gyre Therapeutics positions in Q3 2014 and 14 closed out, a net change of -8 holders.
- The largest Gyre Therapeutics buyer in Q3 2014 was DAFNA Capital Management, an estimated $420K added.
- The largest Gyre Therapeutics seller in Q3 2014 was Franklin Resources, an estimated $6.59M sold.
Based on aggregated 13F filings for Q3 2014.